ONCBeOne Medicines AG
$354.29+5.9% 1Y
$354.29
$260.2752 weeks$377.47
The financials
BeOne Medicines AG by the numbers
Its largest product in Jun 2026 was BRUKINSA at $1.25B, 72% of the disclosed total, well ahead of TEVIMBRA at 13%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Product | Revenue | Share |
|---|---|---|
| BRUKINSA | $1.25B | 72% |
| TEVIMBRA | $229M | 13% |
| XGEVA | $104M | 6.0% |
| Other | $38M | 2.2% |
| BLINCYTO | $37M | 2.1% |
| Other | $25M | 1.5% |
| Amgen Royalty | $19M | 1.1% |
| KYPROLIS | $15M | 0.9% |
| POBEVCY | $9.6M | 0.6% |
| Novartis Broad Markets | $5.0M | 0.3% |
| Collaboration Other | $1.5M | 0.1% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $1.73B (+3214%)
Amgen Royalty grew +108% year on yearKYPROLIS -22% year on year
Segment Latestquarter on quarteryear on year
- BRUKINSA$1.25B$1.25Bquarter on quarter n/ayear on year +31%n/a+31%
- TEVIMBRA$228.5M$228.5Mquarter on quarter n/ayear on year +18%n/a+18%
- XGEVA$104.5M$104.5Mquarter on quarter n/ayear on year +29%n/a+29%
- Other$37.8M$37.8Mquarter on quarter n/ayear on year +79%n/a+79%
- BLINCYTO$36.5M$36.5Mquarter on quarter n/ayear on year +43%n/a+43%
- Other$25.3M$25.3Mquarter on quarter -3.2%year on year +91%-3.2%+91%
- Amgen Royalty$18.8M$18.8Mquarter on quarter +2.9%year on year +108%+2.9%+108%
- KYPROLIS$15.1M$15.1Mquarter on quarter n/ayear on year -22%n/a-22%
- POBEVCY$9.6M$9.6Mquarter on quarter n/ayear on year -14%n/a-14%
- Novartis Broad Markets$5.0M$5.0Mquarter on quarter -5.8%year on year +49%-5.8%+49%
- Collaboration Other$1.5M$1.5Mquarter on quarter -41%year on year +72%-41%+72%
Biotechnology
The closest names by size in the same industry